Late Breaking Abstract - Efficacy and safety of tezepelumab in adults with severe asthma: A randomized phase 2 study

J. Corren (Los Angeles, United States of America)

Source: International Congress 2017 – Late-breaking studies in asthma and COPD
Session: Late-breaking studies in asthma and COPD
Session type: Oral Presentation
Number: 3189
Disease area: Airway diseases

Congress or journal article abstractWebcastSlide presentation

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
J. Corren (Los Angeles, United States of America). Late Breaking Abstract - Efficacy and safety of tezepelumab in adults with severe asthma: A randomized phase 2 study. 3189

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Late Breaking Abstract - Masitinib in severe asthma: Results from a randomized, phase 3 trial
Source: Virtual Congress 2020 – ALERT: Asthma in adults and children
Year: 2020




Late Breaking Abstract - Efficacy and safety of eliapixant in refractory chronic cough: Results of the PAGANINI 12-week, randomized, placebo-controlled Phase 2b study
Source: Virtual Congress 2021 – Airway pharmacology: translational and basic science
Year: 2021


Late Breaking Abstract - Long-term safety and efficacy of benralizumab in severe, uncontrolled asthma: first results of BORA, a randomized, Phase III extension study
Source: International Congress 2018 – Notable Studies in Asthma
Year: 2018



Late Breaking Abstract - LUSTER-1 and -2: randomised controlled trials of fevipiprant in severe asthma
Source: Virtual Congress 2020 – ALERT: Asthma in adults and children
Year: 2020




Late Breaking Abstract - International, prospective real-world study of mepolizumab in patients with severe asthma at one year: REALITI-A
Source: Virtual Congress 2021 – Advances in asthma treatment
Year: 2021


Late Breaking Abstract - Tocilizumab in hospitalized patients with severe COVID-19: an open label, prospective study
Source: Virtual Congress 2021 – Respiratory infections
Year: 2021



Late Breaking Abstract - Duration of amoxicillin-clavulanate for protracted bacterial bronchitis in children: a randomized controlled trial
Source: Virtual Congress 2020 – ALERT: Infection in adults and children
Year: 2020




Late Breaking Abstract - Effectiveness and safety of mepolizumab in real-world clinical practice: the REALITI-A study
Source: International Congress 2019 – New towards old therapies in airway diseases
Year: 2019



Late Breaking Abstract - First-time assessment of efficacy of candidate vaccine to prevent acute exacerbations of chronic obstructive pulmonary disease (AECOPD): multicentre, randomised, controlled, observer-blind phase 2b trial
Source: Virtual Congress 2021 – ALERT: COPD
Year: 2021



Late Breaking Abstract - Predictive value of FeNO in patients with non-specific respiratory symptoms: a randomised controlled trial
Source: International Congress 2017 – Primary care management of respiratory symptoms, allergies, inhalers and adherence
Year: 2017

Late Breaking Abstract - CPAP treatment in the very elderly with Ostructive Sleep Apnea. Pooled results from two multicenter randomized controlled trials
Source: Virtual Congress 2021 – Sleep across the lifespan in the new era of COVID - 19
Year: 2021


Late Breaking Abstract - The impact of regular bisoprolol on recovery with salbutamol in asthma; a double-blind randomised controlled trial
Source: International Congress 2019 – Asthma treatment: novel insights from clinical studies
Year: 2019


Late Breaking Abstract - Adjunctive treatment with oral dexamethasone in adults hospitalised with community-acquired pneumonia: a randomised clinical trial
Source: Virtual Congress 2020 – ALERT: Infection in adults and children
Year: 2020




Abediterol in stable asthma:efficacy, safety and tolerability results from a Phase II, randomised, crossover study
Source: International Congress 2014 – Asthma and COPD management
Year: 2014

Late Breaking Abstract - A randomised, double-blind, placebo controlled, clinical trial evaluating imatinib in patients with severe COVID-19
Source: Virtual Congress 2021 – Late breaking basic and translational science of SARS-Cov2 and COVID-19
Year: 2021



Late Breaking Abstract - Post-trial follow-up after a randomized clinical trial of COVID-19 convalescent plasma.
Source: Virtual Congress 2021 – Emerging evidence on sub-acute and long COVID-19
Year: 2021



Late Breaking Abstract - Can a self-management plan, which includes a four-fold increase in inhaled corticosteroid dose, reduce severe asthma exacerbations: a randomised, pragmatic trial.
Source: International Congress 2017 – Late-breaking findings in asthma and COPD
Year: 2017

Late Breaking Abstract - Effects of a new airway clearance technology in children with cystic fibrosis - A homecare randomized controlled trial
Source: Virtual Congress 2021 – Cystic fibrosis in children: various aspects
Year: 2021


Late Breaking Abstract - Efficacy and safety of azithromycin maintenance therapy in primary ciliary dyskinesia – The BESTCILIA randomized placebo-controlled trial
Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: Intensive care and infection
Year: 2019



Late Breaking Abstract: High-dose vitamin D3 during intensive phase treatment of pulmonary tuberculosis: A double-blind randomised controlled trial
Source: Annual Congress 2010 - Clinical tuberculosis
Year: 2010